Kenilworth, New Jersey

Lumos Pharma Appoints Pediatric Endocrinologist Experienced in Clinical Research and Pharmaceutical Development, Mark Bach, M.D., Ph.D., to Clinical Scientific Advisory Board

Retrieved on: 
Monday, July 26, 2021
Bayer, Kenilworth, New Jersey, Merck & Co., Schering-Plough, Companies, Health care, Pharmaceutical companies, Pharmaceuticals policy

Dr. Bach is a pediatric endocrinologist with 30 years of clinical research and pharmaceutical development experience, including extensive global experience building and leading clinical teams that have successfully launched innovative pharmaceutical products into worldwide markets.

Key Points: 
  • Dr. Bach is a pediatric endocrinologist with 30 years of clinical research and pharmaceutical development experience, including extensive global experience building and leading clinical teams that have successfully launched innovative pharmaceutical products into worldwide markets.
  • Prior to Janssen, Dr. Bach held positions of increasing responsibility in Clinical Research at Merck & Co., Inc., ending his tenure there as Vice President of Clinical Research Operations Worldwide.
  • Early in his career, Dr. Bach conducted extensive clinical and preclinical research on growth hormone, IGF-1 and LUM-201 (MK-0677), with data from this work published in scientific and medical journals.
  • Lumos Pharma, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of therapeutics for rare diseases.

Adagene Announces Clinical Trial Collaboration With Merck to Advance Two Anti-CTLA-4 Monoclonal Antibody Programs (ADG116 and ADG126) in Combination Therapy with KEYTRUDA® (pembrolizumab)

Retrieved on: 
Thursday, July 22, 2021
Cancer treatments, Clinical medicine, Drugs, Cancer immunotherapy, Bayer, Kenilworth, New Jersey, Merck & Co., Schering-Plough, Merck, Pembrolizumab

This collaboration with Merck and the advancement of our global clinical studies represent an important milestone in our comprehensive CTLA-4 clinical development program, said Peter Luo, Ph.D., Co-founder, Chief Executive Officer and Chairman of Adagene.

Key Points: 
  • This collaboration with Merck and the advancement of our global clinical studies represent an important milestone in our comprehensive CTLA-4 clinical development program, said Peter Luo, Ph.D., Co-founder, Chief Executive Officer and Chairman of Adagene.
  • We are fortunate to have the opportunity to explore this combination with Merck and tackle two of the most potent immunotherapy targets.
  • KEYTRUDA is a registered trademark ofMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.,Kenilworth, NJ, USA.
  • In the ADG116-1003 trial, ADG116 has been well tolerated in 17 patients, with no dose-limiting toxicities or unexpected safety signals.

OncXerna Therapeutics to Present at The LifeSci Partners Private Company Summer Symposium

Retrieved on: 
Monday, July 19, 2021
Branches of biology, Biology, Angiology, Medical specialties, Growth factors, Bayer, Kenilworth, New Jersey, Merck & Co., Schering-Plough, Vascular endothelial growth factor, Angiogenesis inhibitor, Angiogenesis

WALTHAM, Mass., July 19, 2021 (GLOBE NEWSWIRE) -- OncXerna Therapeutics, Inc. (OncXerna), a precision medicine company using an innovative RNA-expression based biomarker platform to predict patient responses to its first-in-class targeted oncology therapies, today announced that Laura Benjamin, Ph.D., Founder and CEO of OncXerna, will present at the LifeSci Partners Private Company Summer Symposium taking place virtually from July 21-23, 2021.

Key Points: 
  • WALTHAM, Mass., July 19, 2021 (GLOBE NEWSWIRE) -- OncXerna Therapeutics, Inc. (OncXerna), a precision medicine company using an innovative RNA-expression based biomarker platform to predict patient responses to its first-in-class targeted oncology therapies, today announced that Laura Benjamin, Ph.D., Founder and CEO of OncXerna, will present at the LifeSci Partners Private Company Summer Symposium taking place virtually from July 21-23, 2021.
  • OncXernas approach pairs those patients with OncXernas clinical-stage therapies and known mechanism of action that directly address these biologies, with the goal to substantially improve patient outcomes.
  • OncXerna is targeting patients whose dominant tumor biology is driven by angiogenesis with a focus beyond VEGF to include broader anti-angiogenic pathways.
  • KEYTRUDA is a registered trademark of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA.

RTW Investments-Backed Ji Xing Pharmaceuticals Appoints Joseph Romanelli Chief Executive Officer

Retrieved on: 
Tuesday, July 13, 2021
Professional services, Health, Finance, Clinical trials, Pharmaceutical, Cardiology, Biotechnology, Life sciences, Health sciences, Health care, Bayer, Kenilworth, New Jersey, Merck & Co., Schering-Plough, XING, Merck, Biopharmaceutical, Pharmaceutical industry in China, RTW Investments, Ji Xing Pharmaceuticals, RTW INVESTMENTS, JI XING PHARMACEUTICALS

Ji Xing Pharmaceuticals (Ji Xing or the Company), a biotechnology company focused on bringing innovative medicines to underserved Chinese patients with serious and life-threatening diseases, today announced that Joseph Romanelli has been named Chief Executive Officer and member of the board of directors, effective immediately.

Key Points: 
  • Ji Xing Pharmaceuticals (Ji Xing or the Company), a biotechnology company focused on bringing innovative medicines to underserved Chinese patients with serious and life-threatening diseases, today announced that Joseph Romanelli has been named Chief Executive Officer and member of the board of directors, effective immediately.
  • Ji Xing is backed by RTW Investments, LP (RTW), a leading healthcare-focused entrepreneurial investment firm with a strong track record of creating companies developing life-changing therapies.
  • Romanelli has more than 25 years of biopharmaceutical and biotechnology experience, nearly all with Merck & Co., Inc. (Merck or MSD).
  • Ji Xing also announced the close of its Series B financing from RTW.

NGM Amends Collaboration with Merck to Focus Primarily on Advancing Novel Medicines for Retinal and Cardiovascular and Metabolic (CVM) Diseases

Retrieved on: 
Thursday, July 1, 2021
Bayer, Kenilworth, New Jersey, Merck & Co., Schering-Plough, Companies, Pharmaceutical companies, Health care

NGM disclosed in March 2021 that NGM and Merck were negotiating modifications to certain terms of the agreement to better address their respective evolving priorities.

Key Points: 
  • NGM disclosed in March 2021 that NGM and Merck were negotiating modifications to certain terms of the agreement to better address their respective evolving priorities.
  • Going forward, the collaboration will focus primarily on the development of novel medicines for unmet patient needs in retinal and CVM diseases, including heart failure.
  • Key to the success of our collaboration with NGM has been our companies unwavering commitment to scientific excellence, said Dr. Dean Li, President, Merck Research Laboratories.
  • The amended collaborations primary focus on retinal and CVM diseases builds upon progress with NGM621 and MK-3655, both discovered by NGM under the collaboration.

Alpine Immune Sciences to Collaborate with Merck on Immuno-Oncology Study to Evaluate ALPN-202 in Combination with KEYTRUDA® (pembrolizumab)

Retrieved on: 
Wednesday, June 30, 2021
Oncology, Health, Clinical trials, Research, Science, Pharmaceutical, Biotechnology, Cancer treatments, Clinical medicine, Drugs, Bayer, Kenilworth, New Jersey, Merck & Co., Schering-Plough, Cancer immunotherapy, Breakthrough therapy, Merck, Pembrolizumab, ALPN-202, Alpine Immune Sciences, Inc., ALPN-202, ALPINE IMMUNE SCIENCES, INC.

We are extremely pleased to collaborate with Merck, one of the worlds leading immuno-oncology companies, said Stanford Peng, M.D., Ph.D., President and Head of R&D of Alpine.

Key Points: 
  • We are extremely pleased to collaborate with Merck, one of the worlds leading immuno-oncology companies, said Stanford Peng, M.D., Ph.D., President and Head of R&D of Alpine.
  • This study, in conjunction with NEON-1, ALPN-202s ongoing first-in-human monotherapy trial, will provide insights across a broad spectrum of cancers and lines of therapy.
  • KEYTRUDA is a registered trademark of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA.
  • Alpine Immune Sciences, Inc. is committed to leading a new wave of immune therapeutics.

Merck Animal Health Survey Reveals Pet Owners Need Advice Navigating Their Pets' Transition to Normalcy

Retrieved on: 
Tuesday, June 29, 2021
Merck & Co., Companies, Pharmaceutical companies, Bayer, Kenilworth, New Jersey, Schering-Plough, Merck, Economy of the United States, Pets

"The Bravo, Buddy survey shows that owners want to support their pets but may not know the best way to go about easing this once-in-a-lifetime transition.

Key Points: 
  • "The Bravo, Buddy survey shows that owners want to support their pets but may not know the best way to go about easing this once-in-a-lifetime transition.
  • To aid in this transition, Merck Animal Health and Dr. Lippman are providing important advice to support pet parents who are getting ready to return to their pre-pandemic daily life.
  • To spotlight pets and their owners during the transition, Merck Animal Health also announced the #BravoBuddySweepstakes, in which 12 winners will be selected to receive 12 weeks of pet care support.
  • Merck Animal Health, a division of Merck & Co., Inc., Kenilworth, N.J., USA, is the global animal health business unit of Merck.

Global Brain Tumor Drugs Market Report 2021-2025 & Long-term Forecast to 2030 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, June 23, 2021
Pharmaceutical, Health, Oncology, Life sciences, Companies, Health sciences, Bayer, Kenilworth, New Jersey, Merck & Co., Schering-Plough, Pfizer, Brain tumor, Human brain, Oxford–AstraZeneca COVID-19 vaccine, AstraZeneca

The "Brain Tumor Drugs Global Market Report 2021: COVID-19 Impact and Recovery to 2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Brain Tumor Drugs Global Market Report 2021: COVID-19 Impact and Recovery to 2030" report has been added to ResearchAndMarkets.com's offering.
  • Major players in the brain tumor drugs market are Pfizer Inc., Shimadzu Corporation, Toshiba Medical Systems, Merck & Co. Inc., and AstraZeneca.
  • The brain tumor drugs market consists of sales of drugs which are used to cure a mass growth of abnormal cells in the human brain.
  • Global Brain Tumor Drugs Market, Segmentation By Drugs, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

Merck Foundation announce 'More Than a Mother' and 'Mask up with Care' Media Recognition Awards 2021 for Latin American Countries

Retrieved on: 
Monday, June 21, 2021
Bayer, Kenilworth, New Jersey, Merck & Co., Schering-Plough, Health care, Merck Group, Companies, eMail, Health

Senator, Dr. Rasha Kelej, CEO of Merck Foundation,said, "After celebrating more than 15 winners for "Stay at Home" Media Awards 2020 from Latin American countries, we are all set to launch our new awards for the continent.

Key Points: 
  • Senator, Dr. Rasha Kelej, CEO of Merck Foundation,said, "After celebrating more than 15 winners for "Stay at Home" Media Awards 2020 from Latin American countries, we are all set to launch our new awards for the continent.
  • Hence, I would like to extend my invitation to participate and call for maximum number of applications from the media community present across Latin America."
  • The awards are open to all the journalists in Latin American Countries from Print, Online, Radio and Multimedia Platforms.
  • Entries can be submitted via email to: [email protected]
    The Subject line of the mail should mention the name of the awards.

Merck to Participate in the Guggenheim Biopharma Strategy Series

Retrieved on: 
Thursday, June 17, 2021
Biotechnology, Pharmaceutical, Health, Bayer, Kenilworth, New Jersey, Merck & Co., Schering-Plough, Merck, MRK, Companies, Pharmaceutical industry, Pharmaceutical companies, Merck Group

Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today that Dr. Dean Li, executive vice president and president, Merck Research Laboratories, is scheduled to participate in a virtual fireside chat at the Guggenheim Biopharma Strategy Series with Senior Management to discuss Biopharmas Next Decade: Views from the Top on Global Strategy and Innovation on June 22, 2021, at 9:00 a.m. EDT.

Key Points: 
  • Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today that Dr. Dean Li, executive vice president and president, Merck Research Laboratories, is scheduled to participate in a virtual fireside chat at the Guggenheim Biopharma Strategy Series with Senior Management to discuss Biopharmas Next Decade: Views from the Top on Global Strategy and Innovation on June 22, 2021, at 9:00 a.m. EDT.
  • We demonstrate our commitment to patients and population health by increasing access to health care through far-reaching policies, programs and partnerships.
  • Forward-Looking Statement of Merck & Co., Inc., Kenilworth, N.J., USA
    This news release of Merck & Co., Inc., Kenilworth, N.J., USA (the company) includes forward-looking statements within the meaning of the safe harbor provisions of the U.S.
  • These statements are based upon the current beliefs and expectations of the companys management and are subject to significant risks and uncertainties.